United States Dermatomyositis Drug Market Report 2017

Name: United States Dermatomyositis Drug Market Report 2017
Brand: QYResearch
SKU: U5615704105EN
Price: 3800 USD
Availability: InStock

December 2017 | 114 pages | ID: U5615704105EN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer

Checkout Later

Need Help? Ask a Question

In this report, the United States Dermatomyositis Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Dermatomyositis Drug in these regions, from 2012 to 2022 (forecast).

United States Dermatomyositis Drug market competition by top manufacturers/players, with Dermatomyositis Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

MedImmune LLC
Neovacs SA
Novartis AG
Octapharma AG
Pfizer Inc
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Hope Pharmaceuticals Inc
Idera Pharmaceuticals Inc
KPI Therapeutics Inc
Marathon Pharmaceuticals LLC

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Abatacept
Baricitinib
Dalazatide
Immune Globulin
IMO-8400
Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Hospital
Clinic
Others

If you have any special requirements, please let us know and we will offer you the report as you want.

United States Dermatomyositis Drug Market Report 2017

1 DERMATOMYOSITIS DRUG OVERVIEW

1.1 Product Overview and Scope of Dermatomyositis Drug
1.2 Classification of Dermatomyositis Drug by Product Category
  1.2.1 United States Dermatomyositis Drug Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Dermatomyositis Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Abatacept
  1.2.4 Baricitinib
  1.2.5 Dalazatide
  1.2.6 Immune Globulin
  1.2.7 IMO-8400
  1.2.8 Others
1.3 United States Dermatomyositis Drug Market by Application/End Users
  1.3.1 United States Dermatomyositis Drug Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Others
1.4 United States Dermatomyositis Drug Market by Region
  1.4.1 United States Dermatomyositis Drug Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Dermatomyositis Drug Status and Prospect (2012-2022)
  1.4.3 Southwest Dermatomyositis Drug Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Dermatomyositis Drug Status and Prospect (2012-2022)
  1.4.5 New England Dermatomyositis Drug Status and Prospect (2012-2022)
  1.4.6 The South Dermatomyositis Drug Status and Prospect (2012-2022)
  1.4.7 The Midwest Dermatomyositis Drug Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Dermatomyositis Drug (2012-2022)
  1.5.1 United States Dermatomyositis Drug Sales and Growth Rate (2012-2022)
  1.5.2 United States Dermatomyositis Drug Revenue and Growth Rate (2012-2022)

2 UNITED STATES DERMATOMYOSITIS DRUG MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Dermatomyositis Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Dermatomyositis Drug Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Dermatomyositis Drug Average Price by Players/Suppliers (2012-2017)
2.4 United States Dermatomyositis Drug Market Competitive Situation and Trends
  2.4.1 United States Dermatomyositis Drug Market Concentration Rate
  2.4.2 United States Dermatomyositis Drug Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Dermatomyositis Drug Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES DERMATOMYOSITIS DRUG SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Dermatomyositis Drug Sales and Market Share by Region (2012-2017)
3.2 United States Dermatomyositis Drug Revenue and Market Share by Region (2012-2017)
3.3 United States Dermatomyositis Drug Price by Region (2012-2017)

4 UNITED STATES DERMATOMYOSITIS DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Dermatomyositis Drug Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Dermatomyositis Drug Revenue and Market Share by Type (2012-2017)
4.3 United States Dermatomyositis Drug Price by Type (2012-2017)
4.4 United States Dermatomyositis Drug Sales Growth Rate by Type (2012-2017)

5 UNITED STATES DERMATOMYOSITIS DRUG SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Dermatomyositis Drug Sales and Market Share by Application (2012-2017)
5.2 United States Dermatomyositis Drug Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES DERMATOMYOSITIS DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 MedImmune LLC
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Dermatomyositis Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 MedImmune LLC Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Neovacs SA
  6.2.2 Dermatomyositis Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Neovacs SA Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Novartis AG
  6.3.2 Dermatomyositis Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Novartis AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Octapharma AG
  6.4.2 Dermatomyositis Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Octapharma AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer Inc
  6.5.2 Dermatomyositis Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Eli Lilly and Company
  6.6.2 Dermatomyositis Drug Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Eli Lilly and Company Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 F. Hoffmann-La Roche Ltd
  6.7.2 Dermatomyositis Drug Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Hope Pharmaceuticals Inc
  6.8.2 Dermatomyositis Drug Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Idera Pharmaceuticals Inc
  6.9.2 Dermatomyositis Drug Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 KPI Therapeutics Inc
  6.10.2 Dermatomyositis Drug Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 KPI Therapeutics Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Marathon Pharmaceuticals LLC

7 DERMATOMYOSITIS DRUG MANUFACTURING COST ANALYSIS

7.1 Dermatomyositis Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Dermatomyositis Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Dermatomyositis Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Dermatomyositis Drug Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES DERMATOMYOSITIS DRUG MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Dermatomyositis Drug Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Dermatomyositis Drug Sales Volume Forecast by Type (2017-2022)
11.3 United States Dermatomyositis Drug Sales Volume Forecast by Application (2017-2022)
11.4 United States Dermatomyositis Drug Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

LIST OF TABLES AND FIGURES

Figure Product Picture of Dermatomyositis Drug
Figure United States Dermatomyositis Drug Market Size (K Pcs) by Type (2012-2022)
Figure United States Dermatomyositis Drug Sales Volume Market Share by Type (Product Category) in 2016
Figure Abatacept Product Picture
Figure Baricitinib Product Picture
Figure Dalazatide Product Picture
Figure Immune Globulin Product Picture
Figure IMO-8400 Product Picture
Figure Others Product Picture
Figure United States Dermatomyositis Drug Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Dermatomyositis Drug by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Dermatomyositis Drug Market Size (Million USD) by Region (2012-2022)
Figure The West Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Dermatomyositis Drug Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Dermatomyositis Drug Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Dermatomyositis Drug Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Dermatomyositis Drug Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Dermatomyositis Drug Sales Share by Players/Suppliers
Figure 2017 United States Dermatomyositis Drug Sales Share by Players/Suppliers
Figure United States Dermatomyositis Drug Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Dermatomyositis Drug Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Dermatomyositis Drug Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Dermatomyositis Drug Revenue Share by Players/Suppliers
Figure 2017 United States Dermatomyositis Drug Revenue Share by Players/Suppliers
Table United States Market Dermatomyositis Drug Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Dermatomyositis Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Dermatomyositis Drug Market Share of Top 3 Players/Suppliers
Figure United States Dermatomyositis Drug Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Dermatomyositis Drug Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Dermatomyositis Drug Product Category
Table United States Dermatomyositis Drug Sales (K Pcs) by Region (2012-2017)
Table United States Dermatomyositis Drug Sales Share by Region (2012-2017)
Figure United States Dermatomyositis Drug Sales Share by Region (2012-2017)
Figure United States Dermatomyositis Drug Sales Market Share by Region in 2016
Table United States Dermatomyositis Drug Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Dermatomyositis Drug Revenue Share by Region (2012-2017)
Figure United States Dermatomyositis Drug Revenue Market Share by Region (2012-2017)
Figure United States Dermatomyositis Drug Revenue Market Share by Region in 2016
Table United States Dermatomyositis Drug Price (USD/Pcs) by Region (2012-2017)
Table United States Dermatomyositis Drug Sales (K Pcs) by Type (2012-2017)
Table United States Dermatomyositis Drug Sales Share by Type (2012-2017)
Figure United States Dermatomyositis Drug Sales Share by Type (2012-2017)
Figure United States Dermatomyositis Drug Sales Market Share by Type in 2016
Table United States Dermatomyositis Drug Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Dermatomyositis Drug Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Dermatomyositis Drug by Type (2012-2017)
Figure Revenue Market Share of Dermatomyositis Drug by Type in 2016
Table United States Dermatomyositis Drug Price (USD/Pcs) by Types (2012-2017)
Figure United States Dermatomyositis Drug Sales Growth Rate by Type (2012-2017)
Table United States Dermatomyositis Drug Sales (K Pcs) by Application (2012-2017)
Table United States Dermatomyositis Drug Sales Market Share by Application (2012-2017)
Figure United States Dermatomyositis Drug Sales Market Share by Application (2012-2017)
Figure United States Dermatomyositis Drug Sales Market Share by Application in 2016
Table United States Dermatomyositis Drug Sales Growth Rate by Application (2012-2017)
Figure United States Dermatomyositis Drug Sales Growth Rate by Application (2012-2017)
Table MedImmune LLC Basic Information List
Table MedImmune LLC Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure MedImmune LLC Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure MedImmune LLC Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure MedImmune LLC Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Neovacs SA Basic Information List
Table Neovacs SA Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Neovacs SA Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Neovacs SA Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Neovacs SA Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Novartis AG Basic Information List
Table Novartis AG Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Novartis AG Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Novartis AG Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Novartis AG Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Octapharma AG Basic Information List
Table Octapharma AG Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Octapharma AG Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Octapharma AG Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Octapharma AG Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Pfizer Inc Basic Information List
Table Pfizer Inc Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Pfizer Inc Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Pfizer Inc Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Pfizer Inc Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Eli Lilly and Company Basic Information List
Table Eli Lilly and Company Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eli Lilly and Company Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Eli Lilly and Company Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Eli Lilly and Company Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table F. Hoffmann-La Roche Ltd Basic Information List
Table F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure F. Hoffmann-La Roche Ltd Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Hope Pharmaceuticals Inc Basic Information List
Table Hope Pharmaceuticals Inc Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Hope Pharmaceuticals Inc Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Hope Pharmaceuticals Inc Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Hope Pharmaceuticals Inc Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Idera Pharmaceuticals Inc Basic Information List
Table Idera Pharmaceuticals Inc Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Idera Pharmaceuticals Inc Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Idera Pharmaceuticals Inc Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Idera Pharmaceuticals Inc Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table KPI Therapeutics Inc Basic Information List
Table KPI Therapeutics Inc Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure KPI Therapeutics Inc Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure KPI Therapeutics Inc Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure KPI Therapeutics Inc Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Marathon Pharmaceuticals LLC Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Dermatomyositis Drug
Figure Manufacturing Process Analysis of Dermatomyositis Drug
Figure Dermatomyositis Drug Industrial Chain Analysis
Table Raw Materials Sources of Dermatomyositis Drug Major Players/Suppliers in 2016
Table Major Buyers of Dermatomyositis Drug
Table Distributors/Traders List
Figure United States Dermatomyositis Drug Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Dermatomyositis Drug Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Dermatomyositis Drug Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Dermatomyositis Drug Sales Volume Share Forecast by Region (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume Share Forecast by Region (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

United States Dermatomyositis Drug Market Report 2017

More Publications

Need Help?

Ask a Question

Market Reports